Abstract
AbstractBACKGROUND: Transient gene expression (TGE) provides a rapid way to generate recombinant protein biologics for pre‐clinical assessment. Human embryonic kidney (HEK293) cells have traditionally been used for TGE; however, there is demand from industry for efficient, high‐producing TGE systems that utilize Chinese hamster ovary (CHO) cells. A polyethyleneimine (PEI) ‐based TGE process has been developed for CHO cells using an episomal expression system to generate enhanced recombinant protein titers.RESULTS: A five‐fold improvement in monoclonal antibody (mAb) volumetric productivity was achieved by examining key parameters including transfection medium, cell density, transfection reagent, DNA:reagent ratio, the time of transfer to mild hypothermia and feeding strategy post‐transfection. The Epi‐CHO system allowed for a six‐fold expansion in culture volume post‐transfection without significantly affecting specific productivity. This system generates 400% more mAb per µg of plasmid DNA when compared with a non‐episomal system. In addition, the use of X‐box binding protein 1 to enhance secretion capacity and provide further improvements in mAb production with TGE was investigated.CONCLUSION: Through optimization of key parameters, our results demonstrate the development of a low‐cost, high‐yielding, episomal TGE system that may be adopted during pre‐clinical biologic drug development. Copyright © 2011 Society of Chemical Industry
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Chemical Technology & Biotechnology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.